3-n-(2-fluoroethyl)spiperone has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bidaut, LM; Giladi, N; Goldman, S; Hildebrand, J; Labar, D; Levivier, M; Luxen, A; Przedborski, S; Stanus, E | 1 |
| Coenen, HH; Heiss, WD; Jovkar, S; Laufer, P; Pawlik, G; Rudolf, J; Stöcklin, G; Wienhard, K | 1 |
2 other study(ies) available for 3-n-(2-fluoroethyl)spiperone and Parkinson Disease
| Article | Year |
|---|---|
Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndrome.
Topics: Aged; Basal Ganglia; Brain; Corpus Striatum; Diagnosis, Differential; Female; Functional Laterality; Glucose; Humans; Parkinson Disease; Receptors, Dopamine D2; Spiperone; Tomography, Emission-Computed | 1993 |
PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system.
Topics: Adolescent; Adult; Aged; Brain; Caudate Nucleus; Female; Humans; Male; Middle Aged; Nervous System Diseases; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Spiperone; Tomography, Emission-Computed | 1990 |